Premium
Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis
Author(s) -
Serisier David J.,
Jones Graeme,
Tuck Andrew,
Connett Gary,
Carroll Mary P.
Publication year - 2003
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.10294
Subject(s) - medicine , sputum , cystic fibrosis , exacerbation , pseudomonas aeruginosa , antibiotics , antibiotic sensitivity , ceftazidime , intensive care medicine , respiratory failure , pathology , microbiology and biotechnology , tuberculosis , bacteria , biology , genetics
Abstract A 16‐year‐old male with cystic fibrosis (CF) was admitted to hospital with a severe infective exacerbation. Despite standard management, including conventionally selected intravenous antibiotics for Pseudomonas aeruginosa , chest physiotherapy, and institution of noninvasive ventilation (NIV) for progressive hypercapneic respiratory failure, he continued to deteriorate. Direct sputum sensitivity testing (DSST) revealed a novel combination of antibiotics that resulted in a rapid and remarkable clinical improvement. DSST is a form of “whole” sputum sensitivity testing that provides information on antibiotic synergy, and may more accurately reflect in vivo antibiotic sensitivity patterns in cystic fibrosis. Pediatr Pulmonol. 2003; 35:463–466. © 2003 Wiley‐Liss, Inc.